NASI: Opens Higher Following First Procedure w/ClearPath-HDR Device
Sumbmited From Knobias ClipReport
Shares of North American Scientific, Inc. (NASI) got an opening boost in Friday’s session after it announced the use of its ClearPath-HDR device in a patient for the first time. For use in Accelerated Partial Breast Irradiation (APBI) treatment plans, ClearPath-HDR combines the ease-of-use benefits of balloon brachytherapy products with the customized dose planning benefits of the multi-catheter brachytherapy procedure into one device. This combination also allows doctors to take advantage of a shorter five-day APBI treatment plan, compared with the six to eight weeks required for external beam treatment plans. In addition, ClearPath is implanted through a single incision and is designed to minimize radiation exposure of nearby healthy tissue. The Company estimates that the ClearPath systems will serve an addressable market of more than $500 million.
